natgillin/translations-raw huggingface dataset:
Use of the vector of claim 13 in the manufacture of a medicament, wherein the medicament is for use in a method of inhibiting growth of cancer cells that express STEAP-1 in a subject, the method comprising: administering the vector to said subject, such that the vector delivers the single chain antibody or fragment coding sequence to the cancer cells and the encoded single chain antibody is expressed intracellularly therein. 
Uporaba vektora prema zahtjevu 13, naznačena time, da je za proizvodnju lijeka, gdje je lijek za uporabu u postupku inhibicije rasta stanica raka koje izražavaju STEAP-1 kod osobe, pri čemu postupak obuhvaća: primjenu vektora na spomenutoj osobi, tako da vektor prenosi na stanice raka sekvencu koja kodira protutijelo ili fragment jednostrukog lanca, i zatim ekspresiju unutar stanice tako kodiranog protutijela jednostrukog lanca.
means (308) for time-interleaving data cells of the data slices in a row-column twisted fashion that the input data cells are serially written into interleaving memory in a diagonal direction, and serially read out row-wise; means (308-1) for selectively time-interleaving the encoded L1 signaling data by row-column twisted fashion, wherein the row-column twisted fashion comprises input L1 signaling data cells serially written into an interleaving memory in a diagonal direction, and serially read out row-wise, without considering pilot positions, and outputting an L1, Time Interleaving, TI, block; 
sredstvo (308-1) za selektivno umetanje vremena u kodirani L1 signalni podatak na način prelamanja redova-stupaca, pri čemu način prelamanja redova-stupaca obuhvaća unos u podatkovne stanice signalnog podatka L1 serijski upisanog u memoriju umetanja u dijagonalnom smjeru, i serijsko očitavanje u smjeru redova, bez razmatranja pozicije pilota, i izlaz L1, bloka umetanja vremena, TI;
Dosage form for use according to embodiment 13, wherein the dosage form comprises a single dosing unit or two dosing units, dependent on whether said amount is provided by administration to one nostril or by administration to two nostrils, and is for single use. Dosage form for use according to embodiment 13, wherein the dosage form comprises at least two dosing units, preferably at least three dosing units, more preferably at least four dosing units and most preferably at least five dosing units and is for multiple uses. 
Oblik doziranja za uporabu prema zahtjevu 11, naznačen time da oblik doziranja sadrži jednu jedinicu za doziranje ili dvije jedinice za doziranje, d ovisno o tome da li je navedena količina predviđena za primjenu na jednu nosnicu ili za primjenu na dvije nosnice, te je za jednu primjenu ili pri čemu oblik doziranja sadrži najmanje dvije jedinice za doziranje, poželjno barem tri jedinice za doziranje, poželjnije barem četiri jedinice za doziranje i najpoželjnije najmanje jedinica za doziranje i za višestruke primjene.
a second antibody heavy chain comprising the amino acid sequence selected from the group consisting of SEQ ID NO:115, SEQ ID NO:117, SEQ ID NO:119 and SEQ ID NO:173, and 
drugi teški lanac koji sadrži aminokiselinsku sekvencu odabranu iz skupine koja se sastoji od SEQ ID NO:115, SEQ ID NO:117, SEQ ID NO:119 i SEQ ID NO:173, i
The combination for use according to claim 1 or 2, wherein the salt of donepezil is donepezil hydrochloride. Use of the carbostyril derivative or a salt thereof as set forth in claim 1 or 2 in combination with donepezil or a salt thereof for preparing a medicament for treating Alzheimer's disease. 
Lijek za uporabu za liječenje Alzheimerove bolesti prema zahtjevu 1 ili 2, naznačen time da sol donepezila je donepezil hidroklorid. 4. Uporaba derivata karbostirila ili njegove soli kako je navedeno u zahtjevu 1 ili 2, te donepezila ili njegove soli 15
reacting the compound of Formula LXXVIII with a compound of Formula LXXIII R4X Formula LXXIII to give a compound of Formula LXXXI, 
COX Formula LXXIX čime se dobiva spoj Formule LXXX, reakciju spoja Formule LXXVIII sa spojem Formule LXXIII
Use of mitochondrially targeted E and/or Z isomer of the aliphatic triphenylphosphonium derivative of tamoxifen or their mixture of the general formula I and/or IA for the preparation of a drug for the inhibition of respiration via the mitochondrial complex I. 
Primjena mitohondrijalno ciljanog E i/ili Z izomera alifatskog lanca trifenil fosfonijskog derivata tamoksifena ili njegovih mješavina opće formule I iili IA za pripremu lijeka za inhibiciju respiracije preko mitohondrijskog kompleksa I.
For example, the ancillary group used to improve water solubility/hydrophilicity may be a polyether containing a small number of repeating ethylene oxide (—CH2CH2O—) units. 
Na primjer, pomoćna grupa korištena za poboljšanje topljivosti u vodi/hidrofilnosti može biti polieter koji sadrži mali broj ponavaljućih jedinica etilen-oksida (-CH2CH,O-).
R,R-glycopyrrolate was not effective at the dose of 1 ug/kg, i.th., but it inhibited the bronchospasm by ca. 
R,R-glikopirolat nije bio učinkovit pri dozi od 1 ug/kg, i.th., ali je inhibirao bronhospazam s cca.
In an advantageous embodiment the antibody comprises a light chain encoded by a sequence having at least 80%, 85%, 90%, 95% or 99% identity with one of the nucleotide sequences SEQ ID NO 3 and SEQ ID NO 21. 
- sadrži lagani lanac kojeg kodira sekvenca koja ima barem 80% identičnosti s jednom od nukleotidnih sekvenci SEQ ID NO: 3 i SEQ ID NO: 21 i/ili lagani lanac koji ima barem 80% identičnosti s jednom od polipeptidnih sekvenci SEQ ID NO: 41 SEQ ID NO: 22.
at least 75%, at least 80%, at least 85%, at least 90%, or at least 95% by weight of ApoA-I in said population is in mature form; 
Postupak prema zahtjevu 1, naznačen time što se koraci (b) i (c) ponavljaju sve dok se najmanje 85%, najmanje 90%, ili najmanje 95% proteinske komponente je ugrađeno u lipoproteinske komplekse.
a total amount of protein of at least 60% (w/w) relative to the total weight of the partly denatured whey protein composition, 
ukupnu količinu proteina od najmanje 60 % (tež./tež.) u odnosu na ukupnu težinu pripravka djelomično denaturiranog proteina sirutke, -
In the first object of the invention—a method for intensification of high-viscosity oil production, the specified technical result is achieved in the following way. 
U prvom ostvarenju izuma - postupku za povećanje proizvodnje nafte visoke viskoznosti, navedeni tehnički rezultat se postiže na slj edeći način.
ELISA on purified antibodies. 
ELISA na pročišćenim profutijelima.
m is an integer from 1 to 3; and n is an integer from 2 to 20. 
m je cijeli broj od 1 do 3; i n je cijeli broj od 2 do 20.
For the avoidance of doubt, the term 3(R)-(2-hydroxy-2,2-dithien-2-ylacetoxy)-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2]octane is meant to embrace the salts in dissociated, partially dissociated or undissociated form, for example in aqueous solution. 
Kako bi se izbjegle nedoumice, termin 3(R)-(2-hidroksi-2,2-ditien-2-ilacetoksi)-1-(3-fenoksipropil)-1-azoniabiciklo [2.2.2]oktan obuhvaća soli u disociranom, djelomično disociranom ili nedisociranom obliku, na primjer u vodenoj otopini.
independently represents a fluorine atom, a chlorine atom or a methyl; and R3 represents 
R* neovisno predstavlja atom fluora, klor atom ili metil; i
The compressor may include a plurality of compression cylinders. The liquefied gas treatment system may further include BOG consuming means configured to receive and uses BOG that is compressed while passing through a part of the plurality of compression cylinders included in the compressor. 
Sustav za obradu ukapljenog plina u skladu s patentnim zahtjevom 7, naznačen time što dodatno sadrži element za potrošnju BOG, podešen za prihvat i upotrebu BOG koji se komprimira prilikom prolaska kroz dio od više kompresijskih cilindara (14) koje sadrži kompresor (13).
The composition of claim 7 wherein the spore is selected from the group consisting of B. subtilis, B. amyloliquefaciens, B. licheniformis, B. megaterium, and B. pumilus; and the L-amino acid is selected from the group consisting of L-alanine, L-valine, and L-asparagine. 
Sastav sukladno zahtjevu 7, naznačeno time, da su spore odabrane iz skupine koju čine B. subtilis, B. amyloliquefaciens, B. licheniformis, B. megaterium, i B. pumilus; i L-aminokiselina je odabrana iz skupine koju čine L-alanin, L-valin, i L-asparagin.
The immunogenic composition for use according to any one of claims 1-6 wherein the Streptococcus pneumoniae infection occurs in a lung and the concentration of Zn2+ in the lung tissue is less than 300, 200, 100, 50 or 10µg/kg as measured from a bronchial lavage. 
Imunogeni pripravak namijenjen upotrebi u skladu s bilo kojim od patentnih zahtjeva 1-6, naznačen time što do infekcije bakterijom Streptococcus pneumoniae dolazi u plućima, a koncentracija Zn** u plućnom tkivu je manja od 300, 200, 100, 50 ili 10 ug/kg, što je izmjereno u bronhijalnoj lavaži.
reacting a compound of formula with a suitable compound of formula to form a compound of formula wherein the substituents are described in claim 1, or if desired, converting the compounds obtained into pharmaceutically acceptable acid addition salts. 
[image] s prikladnim spojem formule 2: [image] za tvorbu spoja formule I: [image] pri čemu su supstituenti opisani u zahtjevu 1, ili prema želji, pretvaranje dobivenih spojeva u farmaceutski prihvatljive kiselinske adicijske soli.
(0-2') reducing the nitro group of the compound of formula I' to obtain a compound of formula I" and (0-3') substituting X with PLG by reaction of a reagent PLG-H in the presence of a base, to obtain a compound of formula II". 
(0-2) redukcija nitro-skupine od spoja formule I' u svrhu dobivanja spoja formule I'' dj" i (0-3) supstitucija X s PLG pomoću reakcije reagensa PLG-H u prisutnosti baze, kako bi se dobio spoj 15 formule II''.
The compound according to claim 11, wherein the compound is (E)-2-(3,3-dimethylbut-1-enyl) -4,5-dihydroxyisophthalonitrile. 
Spoj u skladu s patentnim zahtjevom 1, naznačen time, da je spoj (E)-2-(3,3-dimetilbut-1-enil)-4,5- dihidroksi izoftalo nitril.
Buffer is oxygenated with 95% 02/5% C02 for 10 min at 37° C. and pH is adjusted 7.4. 
Bufer se oksidira s 95% O2/5% CO, tijekom 10 minuta na 37 stupnjeva C i pH se adaptira s 7.4.
After evaporation of the solvents under vacuum, the residue was purified by chromatography on silica gel (eluant: 1% to 2% 7N methanolic ammonia in dichloromethane) to give the title compound as a white solid (85 mg, 60%). 
Nakon što su otapala otparena pod vakuumom talog je pročišćen kromatografijom na silika-gelu (eluens: 1 % do 2 % 7N metanolni amonijak u diklormetanu), čime je dobiven spoj iz naslova u obliku bijele krutine (85 mg, 60 %)
a securement structure in the cargo compartment of the vehicle (240) that releasably secures the packaging rack (243) in the cargo compartment (241). 
Prenosivi sustav za kuhanje i dostavu prema zahtjevu 6, naznačen time, da nadalje obuhvaća sljedeće: pričvrsnu konstrukciju u teretnom odjeljku vozila (240), koja odvojivo pričvršćuje rešetkasto postolje za pakiranje (243) u teretnom odjeljku (241).
The method according to claim 3 wherein the disease is irritable bowel syndrome. 
Spoj za uporabu sukladno patentnom zahtjevu 11, naznačeno time, da je bolest sindrom iritabilnog crijeva.
The sole for shoes according to one of claims 10 to 13, characterized in that said vapor-permeable plugs (220a, 220b, 220c, 220d, 220e, 320) are made of materials which do not exhibit oxidation or hydrolysis phenomena upon contact with water. 
Potplat za cipele u skladu s bilo kojim patentnim zahtjevom 10 do 13, naznačen time, da su navedeni paropropusni čepovi (220a, 220b, 2206, 220d, 2206, 320) izrađeni od materijala koji ne trpe oksidacijske ili hidrolitičke promjene nakon dodira s vodom. .
The dose of drug can be controlled by provision of a metered valve. 
Doza lijeka može biti kontrolirana uz uvjet uporabe dozirne pupmice.
The biosensor according to claim 19, comprising said screen printed electrode and said reference electrode as the sole electrodes. 
Biosenzor prema Zahtjevu 19, koji se sastoji od spomenute tiskane mrežaste elektrode i spomenute referentne elektrode, kao jedinih elektroda.
It may be advantageous to incorporate additional thickening agents, such as, for instance, Carbopol Ultrez, or alternatively, Carbopol ETD 2001, available from the B. F. Goodrich Co. 
Može biti korisno uključiti dodatna sredstva za zgušnjavanje, kao što je, na primjer, Carbopol Ultrez, ili alternativno, Carbopol ETD 2001, dostupan od B.F. Goodrich Co.
A pharmaceutical composition comprising the sodium salt of claim 1, 2, 3, 4, 5, 6 or 7, and a pharmaceutically acceptable carrier or diluent. 
Farmaceutski sastav, naznačen time, da obuhvaća natrijevu sol prema zahtjevu 1, 2, 3, 4, 5, 6 ii 7 kao 1 farmaceutski prihvatljiv nosač ili razrjeđivač.
The anhydrous crystalline form of any one of claims 3-6 having an X-ray powder diffraction pattern as shown in Figure 1B. 
Bezvodni kristalinični oblik prema bilo kojem od zahtjeva 3-6 koji ima uzorak rendgenske difrakcije praška kakav je prikazan na Slici IB.
FIG. 2 b shows that the engraved design of the magnetic plate has been transferred with high resolution into the magnetic optically variable ink patch; this latter shows some kind of 3-dimensional effect and a seems to move when the print is looked at from different angles. 
Slika 26 prikazuje kako je ugravirani uzorak u visokoj rezoluciji prenesen s magnetske ploče na otisak magnetske optički varijabilne tinte; potonju odlikuje 3-dimenzionalni učinak, a kada se otisak gleda 1z različitih kuteva čini se kako se kreće.
An injection system for use in injecting a liquid into a tree, the system comprising: 
Sustav za ubrizgavanje koji se koristi za ubrizgavanje tekućine u stablo, naznačen time da sustav obuhvaća:
to give the corresponding amide, i.e. the compound of Formula I. 
kako bi dao odgovarajući amid, spoj s formulom I.
The process of claim 3, wherein said carbonate base is selected from the group consisting of LiHCO3, NaHCO3, KHCO3, Li2CO3, Na2CO3, and K2CO3. 
Postupak u skladu s patentnim zahtjevom 14, naznačen time što navedenu karbonatnu bazu se bira iz skupine koju čine LiHCO»s, NaHCO,, KHCOÂ«4, Lib>CO»s, NaC03 i K2COs.
The method comprising the steps of cutting a micro trench in the area through the first layer into the second layer, placing at least one duct/communication cable in the micro trench so that that duct/communication cable is placed below the first layer, and filling the micro trench so as to restore the road surface. 
- < ugradnje navedenog pluraliteta kanala / kabela u navedeni drugi sloj (L2) ispod navedenog prvog sloja (LI) navedenog glavnog mikro-rova prema navedenom mrežnom rasporedu, pomoću najmanje jednog sredstva vođenja sadržanog u navedenoj stabilizirajućoj napravi; pri čemu se navedeno piljenje, navedeno stabiliziranje i navedeno instaliranje provodi u jednom postupku;
The instrument according to claim 6, wherein said fixating member is adapted for invaginating at least a part of said inflatable device in the stomach wall with stomach-to-stomach staplers, on the inside thereof. 
Uređaj u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što navedeni uređaj ima najmanje dva upravljiva uređaja za rastezanje (410b), prilagođena za rastezanje najmanje dva različita dijela stijenke želuca, gdje je uređaj prilagođen za postoperativno i neinvazivno upravljanje.
A pharmaceutical composition, comprising a protein comprising amino acid sequence SEQ ID NO: 1 or SEQ ID NO:2 capable of stimulating an immune response against Tat protein and capable of transactivation, in combination with a pharmaceutically acceptable carrier. 
Farmaceutski pripravak, naznačen time da sadrži polinukleotid koji kodira protein koji sadrži sekvencu aminokiseline SEQ ID NO:1 ili SEQ ID NO:2 u kombinaciji s farmaceutski prihvatljivim nosačem.
R6, R6a, R6b, R6c and R5d are independently hydrogen, alkyl, aryl, alkylaryl or cycloalkyl, or R6 and R6a together with the nitrogen to which they are attached form an annelated five, six or seven membered heterocycle which may contain 1 to 4 heteroatoms in the ring which are N, O, S, SO, and/or SO2. E-43. 
R$, R*, R&, Ri R* su neovisno vodik, alkil, aril, alkilaril ili cikloalkil, ili RS 1 R& zajedno s atomom dušika na koji su vezani tvore anelirani petero, šestero ili sedmeročlani heterocikal koji može sadržavati 1 do 4 heteroatoma u prstenu koji su N, O, S, SO, i/ili SO».
The offshore aquaculture system of claim 1, wherein the control unit comprises meteorological sensors and is arranged to determine the depth of the cages automatically in respect to measured and anticipated sea conditions, based on measurements from the meteorological sensors. 
Sustav odobalne akvakulture prema zahtjevu 1, pri čemu upravljačka jedinica (150) obuhvaća meteorološke senzore i dizajnirana je tako da može regulirati dubinu rešetaka ovisno o mjerenjima i utvrđenim uvjetima na moru.
Another embodiment of the present invention is use of the rdCMV composition to induce an immune response against CMV in a patient. 
Imunološki efikasna količina kompozicije prema patentnom zahtjevu 2 ili 3 za uporabu u postupku za indukciju imunološkog odgovora protiv CMV kod pacijenta.
The method of claim 80, wherein said supplemental therapy is a weight loss surgery, gastric bypass, gastrectomy, gastric banding, gastric balloon, or gastric sleeve. The method of claim 80, wherein said supplemental therapy is a glucose lowering agent, insulin, GLP1 analogue, biguanide, sulphonylurea, thiazolidinedione, a DPP-4 inhibitor, a bromocriptine formulation, a bile acid sequestrant, metformin, a thiazolidinedione, a SGLT-2 inhibitor, or any combination thereof. 
Himerni peptid za uporabu sukladno patentnom zahtjevu 25 ili 26, naznačen time što dopunska terapija sadrži: (a) operacija gubitka težine, gastrični bypass, gastrektonomija, želučani balon ili želučani rukav; ili (b) sredstvo za snižavanje glukoze, inzulin, GLP1 analog, bigvanid, sulfonilurea, tiazolidindioni, inhibitor dipeptidil _ peptidaze-4 (DPP-4), formulacija bromokriptina, sekvestrant žučne kiseline, "metformin, tiazolidindioni (TZT), SGLT-2 inhibitor, ili bilo koja njihova kombinacija.
The lubricant can be one of magnesium stearate, silicon dioxide, talc, stearic acid, sodium stearyl fumarate, glyceryl behenate or combinations thereof. In some embodiments, the pharmaceutical composition can further comprise an outer coating. 
Kapsula u skladu s bilo kojim patentnim zahtjevom od 12 do 17, naznačena time što se mazivo sastoji od magnezijeva stearata, silicijeva dioksida, talka, stearinske kiseline, natrijeva stearil fumarata, gliceril behenata ili kombinacija navedenog.
Ulipristal acetate or any metabolite thereof, for use in treating or preventing a tumour derived from leiomyomata according to anyone of claims 1 to 5, wherein said metabolite is selected from the group consisting of CDB-3877, CDB-3963, CDB-3236, and CDB-4183 
Ulipristal acetat, 1li bilo koji metabolit izabran iz grupe koja obuhvaća CDB-3877, CDB-3963, CDB-3236, i CDB- 4183 za uporabu radi smanjenja ili zaustavljanja krvarenja u bolesnice koja boluje od uterinih fibroida prema zahtjevu 1 pri čemu se primjenjuje u obliku tablete.
immunising a non-human transgenic mammal with the antigen, wherein the mammal expresses heavy chain-only antibodies which lack CH1 functionality in the transcribed and processed heavy chain mRNA; isolating long-lived plasma cells or memory B-cells from the immunised mammal; 
(a) imuniziranje ne-humanog transgenog sisavca s antigenom, pri čemu sisavac eksprimira antitijela koja sadrže samo teški lanac kojima nedostaje CH1 domena u transkribiranoj i obrađenoj mRNA teškog lanca, te pri čemu su antitijela koja sadrže samo teški lanac eksprimirana iz transgenog lokusa sisavca;
computing an amount (L) of said periodically measured and stored consumption related data to be requested and received from said selected remote meter (RM) on the basis of said status data (TV, ID, NV); and 
- izračunavanja količine (L) navedenih periodički izmjerenih i pohranjenih podataka vezanih uz potrošnju koje zahtijeva i dobiva 1z navedenog odabranog daljinskog brojača (RM) na temelju navedenih trenutnih podataka (TV, ID, NV);
A method for producing at least one IL-23p19 antibody, comprising translating the nucleic acid molecule according to claim 6 or claim 7 under conditions in vitro, in vivo or in situ, such that the IL-23p19 antibody is expressed in detectable or recoverable amounts. 
Postupak za proizvodnju najmanje jednog IL-23p19 protutijela, naznačen time što se sastoji od translacije molekule nukleinske kiseline prema zahtjevu 6 1li zahtjevu 7 pod uvjetima in vitro, in vivo ili in situ, tako da se IL-23p19 protutijelo eksprimira u količinama koje se mogu izmjeriti ili regenerirati.
A method according to claim 9 wherein the sender receives from the server the encrypted transfer specific encryption key and the sender transfers the encrypted data and the encrypted transfer specific encryption key to the receiver over the network. 
Metoda prema zahtjevu 9, u kojoj pošiljatelj prima sa servera enkriptirani specifični enkripcijski ključ prijenosa a pošiljatelj prenosi primatelju putem mreže enkriptirane podatke i enkriptirani specifični enkripcijski ključ prijenosa.
The drug which inhibits complement activity and the at least one immunosuppressive therapy for use according to any one of claims 2 to 4, wherein said immunosuppressive drug is selected from the group consisting of cyclosporin A, tacrolimus, sirolimus, OKT3, a corticosteroid, daclizumab, basiliximab, azathioprene, mycophenolate mofetil, methotrexate, 6-mercaptopurine, anti-T cell antibodies, cyclophosphamide, leflunamide, brequinar, ATG, ALG, 15-deoxyspergualin, a purine analog, rituxan, CTLA-4-Ig (belatacept), IVIg, LF15-0195, and bredinin. 
Anti-C5 antitijelo za uporabu prema bilo kojem od zahtjeva 1 do 13, naznačeno time, što je spomenuto anti-C5 antitijelo ekulizumab ili pekselizumab; pri čemu se spomenuti inhibitor IL-2 bira iz grupe koja se sastoji od ciklosporina A, takrolimusa i sirolimusa; i pri čemu je spomenuti imunosupresivni lijek LF15- 0195.
An apparatus according to claim 1, wherein said adhesive applying means applies said first and said second adhesive portions together to form a strip of adhesive extending along said first surface perpendicular to said first fold. 
Ubrus u skladu s patentnim zahtjevom 1, pri čemu navedeni prvi i drugi prianjajući dijelovi zajedno oblikuju traku prianjajućeg produljenja duž navedene prve površine paralelno s navedenim prvim naborom
A product comprising follicle stimulating hormone (FSH) for use in the treatment of infertility in a patient having serum AMH level of ≥15 pmol/L, wherein the product is to be administered at a dose of, or equivalent to, 0.09 to 0.19 µg human derived recombinant FSH per kg bodyweight of the patient per day, the recombinant FSH including a2, 3- and a2, 6-sialylation wherein 1 % to 50% of the total sialylation is a2, 6- sialyation, and 50% to 99% of the total sialylation is a 2,3- sialyation; and wherein the treatment of infertility comprises a step of determining the serum AMH level of the patient, and a step of administering the dose to a patient having the defined serum AMH level. 
HR P20190023 T1 PATENTNI ZAHTJEVI Proizvod, koji sadrži rekombinantni folikulostimulirajući hormon (FSH) dobiven iz ljudske stanične linije za uporabu kod liječenja neplodnosti kod pacijenta, koji ima razinu AMH u serumu >15 pmol/L, naznačen time da se proizvod administrira u dozi od 0,09 do 0,19 ug rekombinantnog FSH dobivenog iz ljudske stanične linije po kilogramu tjelesne težine pacijenta dnevno; pri čemu liječenje neplodnosti sadrži korak određivanja razine AMH u serumu kod pacijenta i korak administracije doze pacijentu, koji ima definiranu razinu AMH u serumu.
The method of any one of claims 1-20, wherein the first nucleic acid, the second nucleic acid, or both nucleic acids are at least 10 kb. 
prva nukleinska kiselina, druga nukleinska kiselina, ili obje nukleinske kiseline imaju najmanje10 kb; i/ili